These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 2097707)

  • 1. In vivo efficacy of cefcanel daloxate in comparison with cefaclor.
    Magni L; Lionell C
    Scand J Infect Dis Suppl; 1990; 74():185-9. PubMed ID: 2097707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cephalosporin treatment of maxillary sinusitis].
    Köhler W; Schenk P
    Laryngorhinootologie; 1995 Jun; 74(6):355-60. PubMed ID: 7662079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disposition of oral [14C]cefcanel daloxate hydrochloride in healthy male subjects.
    Edwall B; Arvidsson A; Lake-Bakaar D; Lanbeck-Vallén K; Yisak W
    Drug Metab Dispos; 1993; 21(1):171-7. PubMed ID: 8095213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of oral cefcanel daloxate hydrochloride in healthy volunteers and patients with various degrees of impaired renal function.
    Edwall B; Slettevold L; Thurmann-Nielsen E; Walstad R; Torrång A; Dahl K
    J Antimicrob Chemother; 1994 Feb; 33(2):281-8. PubMed ID: 8182009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
    Odenholt I; Cars O
    J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal times above MICs of ceftibuten and cefaclor in experimental intra-abdominal infections.
    Onyeji CO; Nicolau DP; Nightingale CH; Quintiliani R
    Antimicrob Agents Chemother; 1994 May; 38(5):1112-7. PubMed ID: 8067747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibiotic susceptibility of bacteria most commonly isolated from bone related infections: the role of cephalosporins in antimicrobial therapy.
    Jones ME; Karlowsky JA; Draghi DC; Thornsberry C; Sahm DF; Nathwani D
    Int J Antimicrob Agents; 2004 Mar; 23(3):240-6. PubMed ID: 15164964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacokinetics of five oral cephalosporins in calves.
    Soback S; Ziv G; Kurtz B; Paz R
    Res Vet Sci; 1987 Sep; 43(2):166-72. PubMed ID: 3317582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amoxicillin: microbiological activity in vitro and in vivo (author's transl).
    Renzini G; Oliva B; Piccolomini R; Nicoletti M
    Antibiotica; 1973; 11(3-4):117-33. PubMed ID: 4619320
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of cefepime for the treatment of infections caused by extended spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Labombardi VJ; Rojtman A; Tran K
    Diagn Microbiol Infect Dis; 2006 Nov; 56(3):313-5. PubMed ID: 17084784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo antibacterial activity of FK482, a new orally active cephalosporin.
    Mine Y; Yokota Y; Wakai Y; Kamimura T; Tawara S; Shibayama F; Kikuchi H; Kuwahara S
    J Antibiot (Tokyo); 1988 Dec; 41(12):1888-95. PubMed ID: 3209480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of cefcanel in plasma and urine by high-performance liquid chromatography using coupled columns, after administration of the new cephalosporin prodrug cefcanel daloxate hydrochloride.
    Lanbeck-Vallén K; Carlqvist J
    J Chromatogr; 1992 Jul; 578(1):71-6. PubMed ID: 1400788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of cefepime and carbapenems in experimental pneumonia caused by porin-deficient Klebsiella pneumoniae producing FOX-5 beta-lactamase.
    Pichardo C; del Carmen Conejo M; Bernabéu-Wittel M; Pascual A; Jiménez-Mejías ME; de Cueto M; Pachón-Ibáñez ME; García I; Pachón J; Martínez-Martínez L
    Clin Microbiol Infect; 2005 Jan; 11(1):31-8. PubMed ID: 15649301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced clearance of Escherichia coli and Staphylococcus aureus in mice treated with cyclophosphamide and lactoferrin.
    Artym J; Zimecki M; Kruzel ML
    Int Immunopharmacol; 2004 Sep; 4(9):1149-57. PubMed ID: 15251111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Review of oral cephalosporins. Basis for a rational choice].
    Forti IN
    Medicina (B Aires); 1994; 54(5 Pt 1):439-58. PubMed ID: 7658980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
    Roos JF; Bulitta J; Lipman J; Kirkpatrick CM
    J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunocompromised animal models for the study of antibiotic combinations.
    Calandra T; Glauser MP
    Am J Med; 1986 May; 80(5C):45-52. PubMed ID: 3087166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Influence of cefaclor on experimental pyelonephritis (author's transl)].
    Ritzerfeld W
    Infection; 1979; 7 Suppl 6():615-6. PubMed ID: 399249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cefcanel daloxate versus penicillin in acute streptococcal pharyngotonsillitis.
    Grunfeld A; Sinclair P; Nicolle L;
    Can J Infect Dis; 1994 May; 5(3):119-24. PubMed ID: 22346486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo evaluation of tigemonam, a novel oral monobactam.
    Clark JM; Olsen SJ; Weinberg DS; Dalvi M; Whitney RR; Bonner DP; Sykes RB
    Antimicrob Agents Chemother; 1987 Feb; 31(2):226-9. PubMed ID: 3551830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.